BioLife’s OralMatrix, an attempt to turn injectable peptides into tablets

Why it surfaced

The site explains a four-step mechanism built around a buffered microenvironment: the tablet targets gastric acidity and pepsin before releasing the intact peptide in the intestine. It pairs that unusually concrete proposition with simulated gastric-fluid results, a completed Phase 2a insulin program, and 37 granted U.S. patent claims.

BioLife presents OralMatrix, an effervescent oral delivery platform for peptide and protein medicines, including candidates for semaglutide and insulin.